Astellas first joined forces with Immunomic Therapeutics in February, contributing $15 million up front for a vaccine against allergies caused by Japanese red cedar. Now, the duo is entering another partnership, with Astellas handing over $300 million up front for the exclusive license to Immunomic's LAMP-vax technology to develop vaccines for human allergies.
Astellas Pharma is getting a piece of the vaccine pie. The Japanese company is joining forces with U.S.-based Immunomic Therapeutics to develop the latter's vaccine to treat allergies caused by Japanese red cedar.
Astellas Pharma is teaming up with biotech Immunomic Therapeutics on a vaccine that could relieve a common allergy that affects millions in its native Japan.
Immunomic Therapeutics is developing a DNA plasmid-based allergy vax for this allergy, code-named JRC-LAMP-vax, and has been cleared by the U.S. FDA to begin a Phase I clinical trial in Atlanta in June 2012.